ArticleScientific reports2019
Endoscopic Radiofrequency Ablation Prolongs Survival of Patients with Unresectable Hilar Cholangiocellular Carcinoma - A Case-Control Study.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Is endoscopic radiofrequency ablation plus stent placement superior to stent placement alone for the treatment of malignant biliary obstruction? A systematic review and meta-analysis.The Journal of international medical research · 2023Pooled it
- Local palliative therapies for unresectable malignant biliary obstruction: radiofrequency ablation combined with stent or biliary stent alone? An updated meta-analysis of nineteen trials.Surgical endoscopy · 2022Pooled it
- Endobiliary radiofrequency ablation in recurrence and unresectable Perihilar cholangiocarcinoma.BMC gastroenterology · 2025Trial
- Palliative endoscopic biliary drainage for malignant hilar biliary obstruction.Clinical endoscopy · 2026Review
- Endobiliary Radiofrequency Ablation for Hepato-Biliary Diseases: A Narrative Review.Diseases (Basel, Switzerland) · 2025Review
- Endoscopic treatment of unresectable perihilar cholangiocarcinoma: beyond biliary drainage.Therapeutic advances in gastroenterology · 2025Review
- Intraductal ablation therapy for malignant biliary obstruction.Langenbeck's archives of surgery · 2024Review
- Review
- Assessment of safety and adverse events in endoscopic radiofrequency ablation for malignant biliary obstruction.Therapeutic advances in gastroenterology · 2024Article
- Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review.World journal of gastrointestinal endoscopy · 2023Article
- Role of radiofrequency ablation in advanced malignant hilar biliary obstruction.Clinical endoscopy · 2023Review
- Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.Frontiers in oncology · 2023Article
- Impact of endobiliary radiofrequency ablation on survival of patients with unresectable cholangiocarcinoma: a narrative review.Frontiers in oncology · 2023Review
- Efficacy of Endobiliary Radiofrequency Ablation in Preserving Survival, Performance Status and Chemotherapy Eligibility of Patients with Unresectable Distal Cholangiocarcinoma: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2022Article
- Optimal reproduction of a porcine benign biliary stricture model using endobiliary radiofrequency ablation.Scientific reports · 2022Article
- Comparing palliative treatment options for cholangiocarcinoma: photodynamic therapy vs. radiofrequency ablation.Clinical endoscopy · 2022Review
- Review
- Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction over 32-Month Follow-Up.Gastrointestinal tumors · 2022Article
- Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.Scientific reports · 2022Article
- [Recent Updates on Endoscopic Retrograde Cholangiography-guided Intraductal Radiofrequency Ablation for Malignant Biliary Stricture].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The life expectancy of unresectable hilar cholangiocellular carcinomas (CCCs) is very limited and endoscopic radiofrequency ablation (ERFA) of the biliary tract may prolong survival. Our single-center-study retrospectively analysed all CCC cases, in whom ERFAs of the biliary tract were performed between 2012 and 2017 and compared these to historical control cases who received the standard treatment of sole stent application. ERFA was performed in 32 patients with malignant biliary strictures that were mainly caused by Bismuth III and IV hilar CCCs (66%). 14 of these patients received repeated ERFAs, for an overall performance of 54 ERFAs. Stents were applied after examination of all patients (100%). Adverse events occurred in 18.5% of examinations. Case-control analysis revealed that the survival time of cases with unresectable Bismuth type III and IV hilar CCCs (n = 20) treated with combined ERFA and stent application significantly increased compared to controls (n = 22) treated with sole stent application (342 +/- 57 vs. 221 +/- 26 days; p = 0.046). In conclusion, ERFA therapy significantly prolonged survival in patients with unresectable Bismuth type III and IV hilar CCC. As an effective and safe method, ERFA should be considered as a palliative treatment for all these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.